Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
Date:5/16/2008

reating this complex form of breast cancer."

Despite receiving multiple prior lines of anti-cancer therapy, patients who received TYKERB plus trastuzumab in this study experienced:

-- A statistically significant increase in median progression-free survival

versus TYKERB alone (12 weeks vs. 8.1 weeks) (1)

-- A 27 percent reduction in the risk of disease progression [Hazard Ratio:

0.73; p=0.008] (1)

-- A response rate of 10.3 percent versus 6.9 percent. Response rate is a

clinical term that is calculated by complete and partial disappearance

of the tumor.

-- Double the overall clinical benefit rate versus TYKERB alone (24.7

percent vs. 12.4 percent; p=0.01) (1). Clinical benefit rate is

calculated by the response rate and the rate of durable stable disease

(greater than or equal to 6 months).

-- A trend in improved overall survival [Hazard Ratio: 0.75; p=0.106] (1)

The study also demonstrated the activity of TYKERB as a single agent in this patient population, with patients on this arm achieving a median progression free survival of 8.1 weeks and an overall clinical benefit rate of 12.4 percent (1).

The clinical synergy of TYKERB and trastuzumab confirms previous observational findings in preclinical studies and previously reported data from a Phase I study. These latest findings confirm the rationale for further research of this combination in earlier lines of therapy in the metastatic setting and in early stage disease. Additional analysis is underway to explore the benefit that TYKERB plus trastuzumab can offer to less heavily pre-treated patients (1).

Study Background

In this study, 296 patients with HER2 positive breast cancer who had documented progression on trastuzumab treatment in the metastatic setting were eligible to be randomized to receive TYKERB (1000 mg QD) plus trastuzumab (2 mg/kg weekly after 4 mg/kg lo
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 According ... Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), ... Reagents], Application (Immunology, Oncology) & by End ... by MarketsandMarkets, provides a detailed overview of ... market trends, and strategies impacting the global ...
(Date:9/30/2014)... ANGELES , Sept. 30, 2014   Easy ... shopping destination , today announced that it now offers ... . AirSense CPAPs are the first sleep apnea therapy ... it simple and easy to track and share real-time ... overall effectiveness of their CPAP therapy.  In addition, the ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3
... SRI International and the Stanford University School of ... Technology Research Advanced Laboratory), in conjunction with the Institute for Pediatric ... Food and Drug Administration (FDA) to support its work to commercialize ... , , ...
... MUNDELEIN, Ill. , July 22 Sysmex America, ... and information systems, today announced a partnership agreement with Medica ... to laboratories in North America , Mexico ... and Columbia . Sysmex America will be responsible for ...
Cached Medicine Technology:SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 2SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 4SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 5SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 6SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 7Sysmex America and Medica Corporation Announce Distribution Partnership 2Sysmex America and Medica Corporation Announce Distribution Partnership 3
(Date:9/30/2014)... 30, 2014 Keystone Symposia will convene the first ... its 2014-15 Global Health Series on "The Modes ... Hotel immediately following the conclusion of the Grand ... is part of the Keystone Symposia Global Health Series, ... has also funded travel awards for 36 investigators from ...
(Date:9/30/2014)... York, NY (PRWEB) September 30, 2014 ... falling demand have hampered growth in the Bread ... diets have caused consumers to moderate their consumption ... consumer preferences for premium varieties shrunk the market ... products. Successful operators proactively responded by introducing more ...
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... President of ... the Lyme Disease Association., JACKSON, N.J., Oct. 4 The ... "A Clinical Appraisal,of ,Chronic Lyme Disease.," Eleven of its authors also ... by the,Connecticut Attorney General for the development of those Guidelines.,Although the ...
... to stress the disease,s link to heart disease , , THURSDAY, Oct. ... pretty. , An acclaimed rock musician and record producer, he was ... Fox television,s soon-to-be monster hit American Idol . , Then ... diabetes. , Today, with his disease under control, Jackson wants to ...
... technological know how to patient care were demonstrated by ... , Imperials Rector, Sir Richard Sykes, and Professor of ... Darzi, took the PM on a tour of the ... The Institute is at the forefront of medical innovation, ...
... Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ) ... to Chief Scientific Officer of Delivery. Dr. Costantino,will ... new,drug delivery technologies for peptide and protein therapeutics. ... is retiring,tomorrow, October 5, 2007, as was previously ...
... Oct. 4 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM: TSX-V) ... the American,College of Surgeons 93rd Annual Clinical Congress ... CRH will be focused on recruiting General ... its number of Centers for,Colorectal Health. Commenting ...
... Series, new rules for the first time forced players to ... and coaches had to strategize how pitchers were used more ... 12 and under could throw up to six innings per ... an increase in reported cases of young pitchers experiencing arm ...
Cached Medicine News:Health News:NEJM Owes Patients Responsible Journalism, Says Lyme Disease Association 2Health News:Randy Jackson Takes Aim at Diabetes 2Health News:Randy Jackson Takes Aim at Diabetes 3Health News:Prime Minister views innovative health technology at Imperial College London 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 3Health News:CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress 2Health News:How pitching changes little leaguers' shoulders 2Health News:How pitching changes little leaguers' shoulders 3
... stage is a refrigerated design for use as ... use with the 8000 sledge microtome, however, it ... refrigerated stage gives a large working area of ... to provide good adhesion between the specimen and ...
... For some sectioning work, it is necessary to ... State Freezer can be fitted to most microtomes ... -25C or lower, depending on conditions. The equipment ... unit. The cooling stage is best suited for ...
... is necessary to cool a specimen below room ... to most microtomes and will permit specimen cooling ... conditions. The equipment consists of a cooling stage ... best suited for operation with a base sledge ...
... MNL 4404 & 4405 series Freezing Stages fit ... have no moving parts and need only the ... for operation. Freezing starts immediately and ... adjustable so that optimum cutting temperatures can be ...
Medicine Products: